Board of Directors

John L. Bishop

Mr. Bishop joined us as Chief Executive Officer and as a director in April 2002. Mr. Bishop served as President and a director of Vysis, Inc., a genomic disease management company that was acquired by Abbott, from 1993 to 2002 and as Chief Executive Officer from 1996 to 2002. From 1991 until 1993, Mr. Bishop was Chairman and Chief Executive Officer of MicroProbe Corporation, a biotechnology company, and, from 1987 until 1991, of Source Scientific Systems, a biomedical instrument manufacturing company. From 1984 to 1986, Mr. Bishop was President and Chief Operating Officer of Gen-Probe, Inc. From 1968 to 1984, Mr. Bishop held various management positions with American Hospital Supply Company and its affiliates, including a three-year assignment in Japan as an Executive Vice President and Chief Executive Officer of International Reagents Corp., a joint venture between American Hospital Supply Company and Green Cross Corporation. Mr. Bishop currently serves as a director of Conceptus, Inc. In addition, he is a member of the Health Section Governing Board of the Biotechnology Industry Organization and a member of the AdvaMed Dx Board, a division of The Advanced Medical Technology Association.

Cristina H. Kepner

Ms. Kepner joined us as a director in May 1998 and was named Lead Independent Director in February 2013. She was with Invemed from 1978 to 2000, where she served in a variety of capacities. Prior to retiring from Invemed Associates, LLC in December 2000, Ms. Kepner served as Executive Vice President and Corporate Finance Director. Ms. Kepner served as a director of Monogram Biosciences, Inc. from May 1996 until August 2009, when it was acquired by Laboratory Corporation of America Holdings, and as a director of Quipp, Inc. from January 1995, including Chairman of the board of directors from April 2004, until June 2008, when it was acquired by Illinois Tool Works Inc.

Thomas D. Brown

Mr. Brown joined us as a director in February 2006. Mr. Brown joined Abbott Laboratories in 1974 as a sales representative in the Company's Diagnostics Division (ADD). From 1977 through 2002, he held numerous sales, marketing, and general management positions of increasing responsibility within ADD. In 1985 he assumed the position of Director of Sales and in 1986 was promoted to Divisional Vice President of U.S. Sales. In 1987 he was named Divisional Vice President and General Manager, Western Hemisphere Commercial Operations and in 1992 he was named Divisional Vice President, Commercial Operations. He was elected Corporate Vice President Worldwide Diagnostic Commercial Operations in 1993. In 1998, Mr. Brown was named Senior Vice President and President Diagnostics Division, a position held until his retirement from Abbott Labs in 2002. Mr. Brown holds a Bachelor of Arts degree from the State University of New York at Buffalo. He also currently serves on the Board of Directors for Quidel Corporation and Stericycle.

Robert J. Easton

Robert Easton joined us as a director in January 2002. Mr. Easton is a co-founder and co-Chairman of Bionest Partners, a specialty medical business consulting firm.  Previously he was Chairman of Easton Associates, a Managing Director of IBM Healthcare Consulting and President of The Wilkerson Group.  He co-founded and served as a director of Apex Ventures, a Special Purpose Acquisition Company.  Prior to his consulting career Mr. Easton served in managerial roles for the industrial gas and medical products divisions of Union Carbide and Union Carbide Europe.

Thomas L. Gutshall

Mr. Gutshall is co-founder of Cepheid and served as its first CEO, and as Chairman of the Board from August 1996 to February 2013. He was formerly President and COO of CV Therapeutics in Palo Alto. Prior to joining CV Therapeutics in 1995, he was Executive Vice President at Syntex Corporation and a member of the Pharmaceutical Executive Committee. His responsibilities included Syva Company, Syntex Agribusiness, Pharmaceutical and Chemical Operations and Services, Syntex Pharmaceutical Intl. Ltd., and Environmental Health and Safety. Mr. Gutshall also serves as a Director of Silver Bullet Therapeutics and PROFUSA.

Wayne G. Paterson

Mr. Paterson joined us as a Director in April 2015. Mr. Paterson is the Chief Executive Officer and founder at ProCom Rx, a company developing promotional compliance and closed loop marketing platforms for the pharmaceutical industry. From January 2008 to June 2013, Mr. Paterson was employed at Merck Serono, where he served most recently as President, Europe, Canada, Australia, Israel from December 2012 to June 2013 and as Executive Vice President Emerging Markets and Global Head Cardiovascular, Endochrine, Metabolic Medicine from June 2010 to December 2012 and President of Merck Japan from January 2008 to June 2010. Prior to Merck Serono, Mr. Paterson worked at Roche for 10 years. Mr. Paterson also serves as a member of the board of Admedus Ltd. Mr. Paterson brings to our Board approximately 25 years of experience as a senior executive in the international pharmaceutical industry, covering therapeutic areas such as oncology, infectious diseases and cardiovascular and has had extensive operational and financial responsibilities in the emerging, European and
U.S. markets.

David H. Persing, M.D., Ph.D.

Dr. Persing first joined us as a director in May 2004, and became our Executive Vice President and Chief Medical and Technology Officer in August 2005. From 1999 to 2005, Dr. Persing was a research executive and Chief Scientific Officer at Corixa Corporation, a Seattle-based biotechnology company, until its acquisition by GlaxoSmithKline. From 1990 to 1999 he was a member of the Clinical and Research Faculty of the Mayo Clinic in Rochester, Minnesota where he conducted research on hepatitis viruses, tick-borne infections and molecular diagnostics. In 1992 he founded and directed the Molecular Microbiology Laboratory at Mayo Clinic. He has authored over 270 peer-reviewed articles and has served as Editor in Chief for four textbooks on Molecular Diagnostics, the most recent of which was published by ASM press in 2011.

Hollings C. Renton

Mr. Renton joined us as a director in March 2000. Mr. Renton retired from Onyx Pharmaceuticals, Inc., a biopharmaceutical and biotherapeutics company, in March 2008, where he had served as a director beginning in April 1992, President and Chief Executive Officer beginning in March 1993 and Chairman of the Board beginning in June 2003. From 1991 to 1993, he served as President and Chief Operating Officer of Chiron Corporation, a pharmaceutical company, following its acquisition of Cetus Corporation. Prior to the acquisition, he served as President of Cetus Corporation from 1990 to 1991 and as Chief Operating Officer from 1987 to 1990. Mr. Renton also serves as a member of the Boards of Directors of Portola Pharmaceuticals and Kythera Biopharmaceuticals. Mr. Renton’s extensive experience as the chief executive officer of life sciences companies provides useful management perspective and strategic analysis to our Board deliberations.

Glenn D. Steele Jr., M.D., Ph.D.

Dr. Steele joined us as a Director in 2011. Dr. Steele was President and Chief Executive Officer of Geisinger Health System, a physician-led health care system serving multiple regions of New Jersey and Pennsylvania, from March 2001 thru June 2015. Prior to that, he was at the University of Chicago where he served as the Richard T. Crane Professor in the Department of Surgery, Vice President for Medical Affairs, and Dean of the Biological Sciences Division and of the Pritzker School of Medicine. Dr. Steele serves on the boards of Wellcare Health Plans Inc., xG Health Solutions, Inc. as Chairman, PTC Therapeutics and Ingenious Medicine.